Status:
UNKNOWN
Development of a Molecular Diagnosing Platform for Monitoring Oral Hygiene in Diabetic Patients
Lead Sponsor:
General Biologicals Corporation
Collaborating Sponsors:
Mackay Memorial Hospital
Conditions:
Diabetes Mellitus
Periodontal Diseases
Eligibility:
All Genders
25-75 years
Brief Summary
More than ninety percent of adults in Taiwan are suspected to carry periodontal disease, which causes bad breath, swollen and bleeding gums, plaque and even tooth loss. Half of the patients, however, ...
Eligibility Criteria
Inclusion
- 1\. Inclusion condition of diabetes:
- HbAlC≧6.5%
- Glucose(AC)≧126 mg/dL
- 2-h PG≧200mg/dL during an OGTT
- In a patient with classic symptoms of hyperglycemia or hyperglycemic crisis, a random plasma glucose≧200mg/dL 2. Inclusion condition of periodontal disease
- (1) 16 natural teeths and 6 front teeth at lesat (2) Periodontal pocket≧7 mm, and radiographic bone loss≧30%
Exclusion
- People who have oral lesion, dental braces, denture, mouthwash allergy, or serious systemic disease
- People who have ever eaten antibiotics and Anti-inflammatory drugs over the last 6 months
- People who have ever eaten Immunosuppressive drugs, antiepileptic drugs, antihypertensive drugs, or anticoagulant
- Pregnant women or the woman who eat birth control pills
Key Trial Info
Start Date :
May 18 2017
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
February 9 2019
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT03351530
Start Date
May 18 2017
End Date
February 9 2019
Last Update
November 24 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
General Biologicals Corporation
Hsinchu, Taiwan